合成人血管紧张素Ⅱ用于危重儿童儿茶酚胺抵抗性血管扩张性休克:单中心回顾性病例系列
该单中心回顾性病例系列描述了2018年1月至2023年4月在美国一家大型四级儿童医院PICU和CICU收治的23例儿茶酚胺抵抗性血管扩张性休克(CRVS)危重儿童使用辅助性合成血管紧张素Ⅱ的经验。患者中位年龄10.4岁(IQR 1.5-18.5),70%死亡;启动时74%接受一种或多种体外治疗,中位儿童Logistic器官功能障碍-2评分9(IQR 7-11),中位去甲肾上腺素等效剂量(NED)0.65 μg/kg/min(IQR 0.36-0.78)。各评估时点NED和平均动脉压(MAP)均有中位改善;幸存者启动血管紧张素Ⅱ更早(91.5小时 vs 161小时,p=0.23),停药时NED降幅更大(-75% [IQR -96至-50] vs +2.1% [IQR -55至33],p=0.008),MAP升高更多(+15 mmHg [IQR 10-27] vs -1.5 mmHg [IQR -27至18],p=0.052)。作者认为需进一步前瞻性研究探讨最佳启动时机、患者选择及安全性。
要点
- 23例CRVS危重儿童(PICU 20例、CICU 3例)使用辅助性合成血管紧张素Ⅱ,70%死亡,中位年龄10.4岁(IQR 1.5-18.5)。
- 启动血管紧张素Ⅱ时74%(17例)接受一种或多种体外治疗,中位儿童Logistic器官功能障碍-2评分9(IQR 7-11)。
- 启动时中位NED 0.65 μg/kg/min(IQR 0.36-0.78),距首次血管活性药中位127小时(IQR 13-289),中位疗程27小时(IQR 4-68)。
- 各评估时点NED和MAP均有中位改善;幸存者停药时NED降幅-75%(IQR -96至-50)vs 非幸存者+2.1%(IQR -55至33),p=0.008。
- 幸存者停药时MAP变化+15 mmHg(IQR 10-27)vs 非幸存者-1.5 mmHg(IQR -27至18),p=0.052;启动时机91.5小时 vs 161小时,p=0.23。
适用人群与场景
- 美国一家大型四级儿童医院PICU和CICU收治的危重儿童,2018年1月至2023年4月由床边临床医生酌情处方合成血管紧张素Ⅱ。
- 共23例儿茶酚胺抵抗性血管扩张性休克(CRVS)患者,其中PICU 20例、CICU 3例,中位年龄10.4岁(IQR 1.5-18.5)。
处置流程与药物剂量
- 辅助性使用合成血管紧张素Ⅱ,具体剂量、给药途径和频次原文未报告。
- 中位疗程27小时(IQR 4-68);启动时中位NED 0.65 μg/kg/min(IQR 0.36-0.78),距首次血管活性药中位127小时(IQR 13-289)。
研究设计与关键结果
- 单中心回顾性病例系列,23例CRVS危重儿童(PICU 20例、CICU 3例),中位年龄10.4岁(IQR 1.5-18.5),70%死亡。
- 启动血管紧张素Ⅱ时17例(74%)接受一种或多种体外治疗,前24小时中位儿童Logistic器官功能障碍-2评分9(IQR 7-11)。
- 启动时中位NED 0.65 μg/kg/min(IQR 0.36-0.78),距首次血管活性药中位127小时(IQR 13-289),中位疗程27小时(IQR 4-68)。
- 各评估时点NED和MAP均有中位改善;幸存者启动血管紧张素Ⅱ更早(91.5小时 vs 161小时,p=0.23)。
- 停药时幸存者NED降幅-75%(IQR -96至-50)vs 非幸存者+2.1%(IQR -55至33),p=0.008。
- 停药时幸存者MAP变化+15 mmHg(IQR 10-27)vs 非幸存者-1.5 mmHg(IQR -27至18),p=0.052。
证据类型、等级与局限
- 单中心、回顾性病例系列。
- 作者指出需进一步前瞻性研究探讨血管紧张素Ⅱ的最佳启动时机、合适患者选择及该人群中的安全性。
对床旁实践的改变
- 作者认为在CRVS危重儿童中启动血管紧张素Ⅱ后可见NED降低和MAP改善,但需进一步前瞻性研究明确最佳启动时机、患者选择及安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To describe our institutional experience utilizing adjunctive synthetic angiotensin II in critically ill children with catecholamine-resistant vasodilatory shock (CRVS).
DESIGN: Single-center, retrospective case series.
SETTING: PICU and cardiac ICU (CICU) at a large, quaternary children's hospital in the United States.
PATIENTS: Twenty-three pediatric patients with CRVS who were prescribed synthetic angiotensin II at the discretion of bedside clinicians from January 2018 to April 2023.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Twenty-three patients (20 in PICU, 3 in CICU) with a median age of 10.4 years (interquartile range [IQR] 1.5-18.5) received angiotensin II over the study period, 70% of whom died. At the time of angiotensin II initiation, 17 patients (74%) were receiving one or more forms of extracorporeal therapy, and median Pediatric Logistic Organ Dysfunction-2 Score-2 in the prior 24 hours was 9 (IQR 7-11). The median time between initiation of the first vasoactive agent and angiotensin II was 127 hours (IQR 13-289), and the median total norepinephrine equivalent (NED) at initiation was 0.65 μg/kg/min (IQR 0.36-0.78). The median duration of therapy was 27 hours (IQR 4-68), and at each timepoint assessed, patients had median improvement in NED and mean arterial pressure (MAP) with treatment. Survivors initiated angiotensin II nearly 3 days earlier in vasoactive course (91.5 hr vs 161 hr, p = 0.23), and had both greater reduction in NED (-75% [IQR -96 to -50] vs +2.1% [IQR -55 to 33], p = 0.008) and greater increase in MAP (+15 mm Hg [IQR 10-27] vs -1.5 mm Hg [IQR -27 to 18], p = 0.052) at angiotensin II discontinuation.
CONCLUSIONS: We demonstrate reduction in NED and improved MAP following initiation of angiotensin II in critically ill children with CRVS. Further prospective work is needed to examine optimal timing of angiotensin II initiation, appropriate patient selection, and safety in this population.
参考来源
- Tezel O, Hutson TK, Gist KM, et al. Utilization of Synthetic Human Angiotensin II for Catecholamine-Resistant Vasodilatory Shock in Critically Ill Children: A Single-Center Retrospective Case Series. Crit Care Explor. 2023. PMID: 37711646. doi:10.1097/CCE.0000000000000978
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。